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Abstract
 
Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin’s lymphoma and autoim-
mune disease. However, the cellular and molecular pathways for B cell depletion remain undefined
because human mechanistic studies are limited. Proposed mechanisms include antibody-, effector
cell–, and complement-dependent cytotoxicity, the disruption of CD20 signaling pathways,
and the induction of apoptosis. To identify the mechanisms for B cell depletion in vivo, a new
mouse model for anti-CD20 immunotherapy was developed using a panel of twelve mouse
anti–mouse CD20 monoclonal antibodies representing all four immunoglobulin G isotypes.
Anti-CD20 antibodies rapidly depleted the vast majority of circulating and tissue B cells in an
isotype-restricted manner that was completely dependent on effector cell Fc receptor expression.
B cell depletion used both Fc
 
 
 
RI- and Fc
 
 
 
RIII-dependent pathways, whereas B cells were not
eliminated in FcR common 
 
  
 
chain–deficient mice. Monocytes were the dominant effector
cells for B cell depletion, with no demonstrable role for T or natural killer cells. Although most
anti-CD20 antibodies activated complement in vitro, B cell depletion was completely effective
in mice with genetic deficiencies in C3, C4, or C1q complement components. That the innate
monocyte network depletes B cells through Fc
 
 
 
R-dependent pathways during anti-CD20 immu-
notherapy has important clinical implications for anti-CD20 and other antibody-based therapies.
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Introduction
 
B lymphocytes are the origin of humoral immunity, represent
a substantial portion of hematopoietic malignancies, and con-
tribute to autoimmunity. Consequently, cell surface mole-
cules expressed by B cells and their malignant counterparts
are important targets for immunotherapy. CD20, a B cell–
specific member of the MS4A gene family with four
membrane-spanning domains, is expressed on the surface
of immature and mature B cells and their malignant coun-
terparts (1). Chimeric or radiolabeled mAb-based therapies
directed against CD20 represent an effective treatment for
non-Hodgkin’s lymphoma (2–6). Clinical studies indicate
that anti-CD20 mAb therapy also ameliorates the manifes-
tations of rheumatoid arthritis, idiopathic thrombocytopenic
purpura, and hemolytic anemia, as well as other immune-
mediated diseases (7, 8). Despite the effectiveness of this
therapy, relatively little is known about why CD20 is such
a potent target molecule for therapy. Moreover, the precise
molecular and cellular mechanisms for B cell depletion and
tumor regression after anti-CD20 mAb treatment and the
development of resistance to anti-CD20 immunotherapy
remain uncertain (9).
Competing hypotheses are used to explain the therapeutic
efficacy of anti-CD20 mAbs in vivo. In one model, CD20
serves as a membrane-embedded target for mAb-mediated
depletion of B cells through activation of the innate immune
system or the initiation of effector mechanisms (10–12).
Thus far, major effector mechanisms include C- and Ab-
dependent cytotoxicity (10, 13). Rituximab, a chimeric
human IgG1 anti–human CD20 mAb is highly effective in
inducing classical pathway C activation and C-dependent
cytotoxicity of freshly isolated lymphoma cells and B cell
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lines (10, 14–17). Rituximab also activates C in vivo in
both patients (18) and primates (19). Furthermore, tumor
cell expression of C regulatory proteins, including CD59,
is associated with resistance to anti-CD20 therapy (14,
20). Although many consider C-dependent cytotoxicity
to be the major pathway used by Rituximab to deplete
human lymphoma cells in vitro and in vivo (14–16, 21–
23), others have found that the susceptibility of tumor
cells to C-mediated lysis and expression of C inhibitors
CD46, CD55, and CD59 on tumor cells does not pre-
dict the outcome of Rituximab therapy (24). Other Ab-
dependent effects also appear important because a chimeric
anti-CD20 mAb of an isotype different than that used
clinically does not deplete normal B cells in nonhuman
primates (25) and the antitumor effect of anti-CD20 mAb
depends in part on immune activation through Fc recep-
tors (Fc
 
 
 
R) for IgG (26). Alternatively, anti-CD20 mAb
treatment alters transmembrane Ca
 
2
 
  
 
transport and B cell
function, which disrupts progression through cell cycle (1)
and can induce B cell apoptosis (13, 27). It is difficult to
differentiate between these hypotheses in vivo due to the
complexities of carrying out mechanistic studies in hu-
mans undergoing immunotherapy (9). Moreover, human
studies primarily focus on changes in blood, which con-
tains 
 
 
 
2% of the B cells outside of the BM. Thus, it is dif-
ficult to accurately ascertain the effects of anti-CD20 ther-
apies on the majority of B cells, which are found in
peripheral lymphoid tissues. As with human CD20, mouse
CD20 is also B cell specific, being first expressed during
the pre–B to immature B cell transition, with continued
expressed during maturation until plasma cell differentia-
tion (28). Therefore, to examine how mAb binding to
CD20 initiates effector systems that lead to B cell deple-
tion, we developed a unique panel of mouse anti–mouse
CD20 mAbs (28). We have used these mAbs to establish a
preclinical mouse model of anti-CD20 mAb immunother-
apy amenable to mechanistic studies and genetic manipu-
lation. This model has allowed a comparison between the
existing in vitro and in vivo data that shape current models
of how anti-CD20 therapies work, and has resulted in
mechanism-based predictions of the biological outcome of
mAb therapy in vivo.
 
Materials and Methods
 
Abs and Immunofluorescence Analysis.
 
Mouse CD20–specific
mouse mAbs were as described previously (28). Other mAbs in-
cluded the following: CD19 mAb MB19-1 (29), B220 mAb
RA3-6B2 (provided by R. Coffman, DNAX Corp., Palo Alto,
CA), and Thy1.2 mAb (Caltag Laboratories). Isotype-specific and
anti–mouse Ig or IgM Abs were from Southern Biotechnology
Associates, Inc. Single cell leukocyte suspensions were stained on
ice using predetermined optimal concentrations of each Ab for
20–60 min as described previously (30). Cells with the forward
and side light scatter properties of lymphocytes were analyzed on
FACScan™ or FACSCalibur™ flow cytometers (Becton Dickin-
son). Background staining was determined using unreactive con-
trol mAbs (Caltag Laboratories) with gates positioned to exclude
 
 
 
98% of the cells.
 
Mice.
 
CD20
 
 
 
/
 
  
 
and WT littermates were as described previ-
ously (28). Fc
 
 
 
RI
 
 
 
/
 
  
 
and Fc
 
 
 
RIII
 
 
 
/
 
  
 
mice were as described
previously (31). C57BL/6, Fc
 
 
 
RII
 
 
 
/
 
  
 
(B6,129S-Fcgr2tm1Rav),
Fc
 
 
 
RIII
 
 
 
/
 
  
 
(C57BL/6-Fcgr3tm1Sjv), Beige (C57BL/6-
 
Lyst
 
bg/bg
 
),
Perforin
 
 
 
/
 
  
 
(C57BL/6-Pfptm1Sdz), CSF1
 
op 
 
(
 
Csf1
 
op
 
), and nude
(C57BL/6-
 
Hfh11
 
nu
 
) mice were from The Jackson Labora-
tory. FcR common 
 
  
 
chain (FcR
 
 
 
)-deficient mice (FcR
 
 
 
 
 
/
 
 
 
,
B6.129P2-
 
Fcerg1
 
tm1
 
) were from Taconic Farms. C1q
 
 
 
/
 
  
 
mice as
described previously (32) were provided by G. Kelsoe (Duke
University, Durham, NC) with the permission of M. Walport
(Imperial College, London, UK). LAT
 
 
 
/
 
  
 
mice were from W.
Zhang (Duke University, Durham, NC; reference 33). C3
 
 
 
/
 
 
 
and C4
 
 
 
/
 
  
 
mice were from M. Carroll (Center for Blood Re-
search, Boston, MA; reference 34). Macrophage-deficient mice
were generated by tail vein injections of clodronate-encapsulated
liposomes (0.1 ml/10 g body weight; Sigma-Aldrich) on days
 
 
 
2, 1, and 4 as described previously (35). All mice were housed
in a specific pathogen-free barrier facility and first used at 2–3 mo
of age. These studies were approved by the Animal Care and Use
Committee of Duke University.
 
Immunotherapy.
 
Sterile anti–mouse CD20 and isotype control
mAbs (0.5–250 
 
 
 
g) in 200 
 
 
 
l PBS were injected through lateral
tail veins. All experiments used 250 
 
 
 
g mAb unless indicated
otherwise. Blood and spleens were collected at 1 h and 2, 4, 7,
28, 48, 50, 52, 54, 56, or 58 d after treatment. Blood leukocyte
numbers were quantified by hemocytometer after red cell lysis,
with B220
 
  
 
B cell frequencies determined by immunofluores-
cence staining with flow cytometry analysis. Ab doses in humans
and mice were compared using the Oncology Tool Dose Calcu-
lator (www.fda.gov/cder/cancer/animalframe.htm).
 
C Assays.
 
WT mouse spleen B cells were purified (
 
 
 
93%
B220
 
 
 
) by T cell removal using Thy1.2 mAb-coated magnetic
beads (Dynal). Quantification of C-mediated B cell killing in
vitro was as described previously (36). Spleen B cells were incu-
bated with each anti-CD20 mAb (0.5 
 
 
 
g/ml) and baby rabbit C
(diluted 50-fold; GIBCO BRL) for 2 h at 37
 
 
 
C. PBS was added
to each tube with incubation for 4 h at 37
 
 
 
C before the cells were
washed and stained with propidium iodide (PI) and anti-B220
mAb. PI exclusion was determined by flow cytometry analysis.
 
Statistical Analysis.
 
All data are shown as means 
 
  
 
SEM. The
Student’s 
 
t
 
 test was used to determine the significance of differ-
ences between population means.
 
Results
 
Anti-CD20 mAb Depletion of B Cells In Vivo.
 
12 mouse
anti–mouse CD20 mAbs, with representatives of each IgG
isotype, were assessed for their ability to bind B cells and de-
plete them in vivo. Each mAb reacted uniformly with
CD19
 
  
 
primary B cells in vitro with characteristic mean
fluorescence intensities that were independent of mAb iso-
type (Fig. 1 A; not depicted). When mAb reactivity with
primary B cells was assessed over a range of mAb concentra-
tions, most mAbs reached saturating levels of staining when
used at concentrations between 1–10 
 
 
 
g/ml (Fig. 1 B; not
depicted). On average, 50% maximal log mAb staining was
achieved at mAb concentrations of 
 
 
 
0.5 
 
 
 
g/ml (Fig. 1 B,
arrows). When all mAbs were used at 0.5 
 
 
 
g/ml, each mAb
reacted uniformly with CD19
 
  
 
primary B cells with charac-
teristic low to high mean fluorescence intensities (Fig. 1 C
and Table I). Similar results were obtained using a mouse 
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CD20 cDNA-transfected pre–B cell line with anti–mouse Ig
secondary antibody (unpublished data). Based on this analy-
sis, the MB20-1 mAb represented mAbs with the lowest rel-
ative affinity/avidity, whereas the MB20-18 mAb reacted
strongly with B cells and stained B cells at the highest levels
of all 12 anti-CD20 mAbs (Table I). Thus, each mAb re-
acted specificity with B cells and displayed reasonable bind-
ing characteristics as assessed by flow cytometry.
Each anti–mouse CD20 mAb was given to mice at 250
 
 
 
g/mouse, a single dose 
 
 
 
10-fold lower than the 375 mg/
m
 
2 
 
dose primarily given four times for anti-CD20 therapy in
humans (2–6). Under these conditions, multiple mAbs had
potent and long-lasting effects on peripheral B cell numbers,
whereas other mAbs had heterogeneous in vivo effects (Fig.
2). The effectiveness of mAb-induced B cell depletion from
the circulation by day 2 and spleen by day 7 correlated
closely with mAb isotype (Table I and Fig. 2, A and B),
with IgG2a 
 
  
 
IgG1 
 
  
 
IgG2b 
 
  
 
IgG3. MB20-11 and other
IgG2a mAbs (MB20-6 and MB20-16) depleted 
 
 
 
95% of
blood B cells and 
 
 
 
93% of splenic B cells. The few remain-
ing peripheral B cells primarily represented phenotypically
immature cells emerging from the BM (unpublished data).
The MB20-11 mAb depleted significant numbers of circu-
lating B cells when given as a single dose as low as 0.5 
 
 
 
g/
mouse, whereas significant depletion of spleen B cells by
day 7 required a fivefold higher mAb dose of 2.5 
 
 
 
g/mouse
(Fig. 2 C). Equally striking was the finding that a single
injection of MB20-11 mAb depleted circulating B cells
within 1 h of mAb treatment, with a durable effect for 
 
 
 
57 d
before B cells began to repopulate the circulation and spleen
(Fig. 2 D). By contrast, none of the mAbs had significant
effects when given to CD20
 
 
 
/
 
  
 
mice and isotype-control
mAbs given under identical conditions did not affect B cell
numbers (Fig. 2; not depicted). Likewise, circulating and
tissue Thy1.2
 
  
 
T cell numbers were unchanged in anti-
CD20 mAb-treated mice (Fig. 2 A; unpublished data), con-
sistent with B cell–restricted CD20 expression (28).
 
Role for Fc
 
 
 
R in B Cell Depletion.
 
The role of the in-
nate immune system in B cell depletion by anti-CD20
mAb treatment was assessed using Fc
 
 
 
R-deficient mice
(37). Mouse effector cells express three different Fc
 
 
 
R
classes for IgG: the high affinity Fc
 
 
 
RI (CD64), and the
low affinity Fc
 
 
 
RII (CD32) and Fc
 
 
 
RIII (CD16) mole-
cules (38). Fc
 
 
 
RI and Fc
 
 
 
RIII are hetero-oligomeric com-
plexes in which the respective ligand-binding 
 
  
 
chains
associate with a common 
 
  
 
chain (FcR
 
 
 
). FcR
 
  
 
chain ex-
pression is required for Fc
 
 
 
R assembly and for Fc
 
 
 
R trig-
gering of effector functions, including phagocytosis by
macrophages and cytotoxicity by NK cells (37). High af-
Figure 1. Reactivity of anti-CD20 mAbs with spleen B cells. (A) Fluo-
rescence intensity of CD19  cells stained with representative anti-CD20
(solid lines) or isotype-matched control (dashed line) mAbs (10  g/ml).
(B) Mean fluorescence intensity (MFI) of anti-CD20 mAb staining over a
range of mAb concentrations. Arrows indicate mean intensities of mAb
staining when used at 0.5  g/ml. (C) Fluorescence intensity of CD19 
cells stained with anti-CD20 (solid lines) or isotype-matched control
(dashed line) mAbs (0.5  g/ml). In all cases, mAb staining was visualized
using PE-conjugated isotype-specific secondary Abs with flow cytometry
analysis. Results represent those obtained in three or more experiments.
 
Table I.
 
Mouse Anti–Mouse CD20 mAbs
 
Percent in vivo depletion
 
b
 
Isotype Ab B cell reactivity
 
a
 
Blood Spleen
IgG1 MB20-1 69 95 
 
  
 
3 93 
 
  
 
3
MB20-2 209 88 
 
  
 
1 67 
 
  
 
8
MB20-14 166 94 
 
  
 
4 77   8
IgG2a MB20-6 96 99   1 93   5
MB20-11 158 98   1 92   2
MB20-16 170 99   1 95   0
IgG2b MB20-7 525 82   9 36   36
MB20-8 240 94   13     18
MB20-10 317 91   13     9
MB20-18 729 96   1 74   3
IgG3 MB20-3 47 1   11     3
MB20-13 603 18   13     1
aValues represent the mean linear fluorescence intensity for immunoflu-
orescence staining of spleen CD19  B cells with 0.5  g/ml of each
MB20 mAb (see Fig. 1 C). Splenocyte staining was visualized using iso-
type-specific secondary Abs. Control staining was  6 in all cases.
bValues (  SEM) indicate the percent of B220  B cells depleted from
blood or spleen 7 d after mAb treatment (n   3) compared with iso-
type-matched control mAbs.Monocytes Mediate B Cell Depletion during Anti-CD20 Immunotherapy 1662
finity Fc RI preferentially binds monomeric IgG2a  
IgG2b   IgG3/IgG1, whereas the two low affinity recep-
tors bind polymeric IgGs of different isotypes (39). Fc RIII
binds IgG2a   IgG1   IgG2b    IgG3 (39).
In contrast to almost complete B cell depletion in WT
mice (Fig. 2), MB20-11 mAb treatment reduced circulating
B cell numbers by only 20–35% in FcR  /  mice over 4 d
(Fig. 3 A), with no effect from days 7 to 18 (unpublished
data). Moreover, MB20-11 mAb treatment actually in-
creased spleen B cell numbers in FcR  /  mice compared
with control mAb–treated littermates (Fig. 3, B and C), pre-
dominantly due to increased numbers of immature B cells
(unpublished data). An isotype-matched control mAb had
no significant effect in FcR  /  mice. In Fc RI /  mice,
the MB20-11 mAb induced an initial decrease in B cell
numbers at 1 h, but incomplete depletion of circulating B
cells on day 2. MB20-11 mAb treatment only partially de-
pleted B cells in Fc RI /  mice with 21% of spleen B cells
persisting at day 7 compared with control mAb–treated lit-
termates. By contrast, the MB20-11 mAb depleted circulat-
ing and tissue B cells by  95% in WT, Fc RII / , and
Fc RIII /  mice by day 7. Identical results were obtained
using two independent Fc RIII /  mouse (31, 40) lines
(unpublished data). B cell depletion by the IgG1 MB20-1
and IgG2b MB20-18 mAbs was similarly affected by FcR 
chain deficiency. Circulating B cells were not significantly
reduced by MB20-1 mAb treatment of FcR  /  mice,
whereas circulating B cells were depleted in WT mice (Fig.
3 D). Likewise, spleen B cells were not significantly reduced
by MB20-1 mAb treatment of FcR  /  mice, whereas
spleen B cell numbers were reduced by 93% in WT mice.
Circulating B cells were significantly reduced by MB20-18
mAb treatment of FcR  /  mice, but not to the same ex-
tent as occurred in WT mice (Fig. 3 E). However, spleen B
cells were not significantly reduced by MB20-18 mAb
treatment of FcR  /  mice, whereas spleen B cell numbers
were reduced by 74% in WT mice. Thus, anti-CD20 mAb
therapy primarily depleted B cells through pathways that re-
quire FcR  chain expression.
C Does Not Facilitate B Cell Depletion. Because C acti-
vation is considered a major mechanism for B cell deple-
tion during anti-CD20 mAb therapy, the role of C in B
cell depletion by anti-CD20 mAb treatment was assessed
using C-deficient (34) and C1q-deficient (32) mice. The
C-activating ability of each anti-CD20 mAb was first as-
sessed in vitro. In the presence of C, most of the anti-
CD20 mAbs induced significant B cell lysis as indicated by
PI uptake relative to isotype-matched control mAbs, al-
though cytotoxic capability varied between Abs (Fig. 4 A).
Without C, none of the anti-CD20 mAbs induced B cell
PI uptake or apoptosis during these in vitro assays (unpub-
lished data). The MB20-18 mAb initiated the most potent
C-dependent lysis of B cells, although the MB20-11 mAb
was also effective in inducing significant C-mediated B cell
lysis in vitro. However, the ability of each mAb to induce
C-dependent B cell killing in vitro did not correlate with
the ability of each mAb to deplete B cells in vivo (Fig. 2 B).
Moreover, the MB20-11 mAb effectively cleared all blood
and  90% of spleen B cells in C3 /  and C4 /  mice (Fig.
4 B). This observation was not mAb isotype specific be-
cause the MB20-1 and MB20-18 mAbs effectively depleted
blood and spleen B cells to similar extents in both C3 / 
and WT mice (Fig. 4, C and D). Thus, anti-CD20 mAb
therapy primarily depletes B cells through Fc R-depen-
dent and C3-, C4-, and C1q-independent mechanisms.
Monocytes Mediate B Cell Depletion In Vivo. Because the
depleting ability of anti-CD20 mAb treatment correlated di-
Figure 2. B cell depletion in vivo. (A) Representative B cell depletion
from blood (day 2) and spleen (day 7) after MB20-11 or isotype-matched
control mAb treatment of WT or CD20 /  mice as determined by immuno-
fluorescent staining with flow cytometry analysis. Numbers indicate the
percentage of gated B220  B cells. (B) Total numbers (  SEM) of blood
(days 2 or 7, per ml) and spleen (day 7) B cells after treatment of two or
more WT littermates with MB20 or isotype control mAbs. Significant
differences between mean results for MB20 or isotype control mAb–
treated mice are indicated. *, P   0.05; **, P   0.01. (C) Blood and
spleen B cell numbers (  SEM) in WT littermates 7 d after treatment
with MB20-11 mAb at different doses (two or more mice per data point).
Significant differences between untreated (0) and mAb-treated mice are
indicated. **, P   0.01. (D) Blood and spleen B cell numbers (  SEM) in
WT mice after MB20-11 ( ) or isotype control ( ) mAb treatment on
day 0 (five or more mice per group). The value shown after time 0 repre-
sents data obtained at 1 h.Uchida et al. 1663
rectly with mAb isotype and Fc R expression, the contribu-
tions of NK cells, T cells, and macrophages to Fc R-mediated
B cell depletion was determined. Mice rendered macrophage
deficient by treatment with liposome-encapsulated clodronate
did not significantly deplete circulating B cells by 1 h after
MB20-11 mAb treatment, and had normal numbers of circu-
lating B cells for up to 7 d (Fig. 5 A). Similarly, spleen B cell
numbers in clodronate-treated mice were only decreased by
39% on day 7 relative to control mAb–treated littermates (Fig.
5 B). Mice with tissue-specific losses in macrophage subpopu-
lations (41) due to CSF-1 deficiency (CSF-1op) were also slow
to clear circulating B cells after MB20-11 mAb treatment, and
only depleted 84% of phenotypically mature spleen B cells by
day 7 (Fig. 5). By contrast, athymic nude and LAT /  mice
that lack functional T cells (33) depleted  96% of blood and
spleen B cells. Likewise, anti-CD20 mAb treatment removed
 95% of circulating and spleen B cells in beige and perforin / 
mice (Fig. 5) with defective NK cell function (42). These
findings implicate both CSF-1–dependent and –independent
macrophage subsets as the major effector cells for depletion of
CD20  B cells in vivo, and essentially exclude T cell–, NK
cell–, and perforin-dependent mechanisms.
Discussion
These studies reveal that the phagocytic network of the
innate immune system is primarily responsible for eliminat-
ing circulating and tissue B cells after anti-CD20 mAb
therapy in mice (Figs. 3 and 5). Likely mechanisms for
B cell depletion include Fc R-mediated phagocytosis of
mAb-coated B cells or the secretion of cytolytic or un-
known cytotoxic factors by activated macrophages. Macro-
phages activated by Fc R-dependent pathways may also
release inflammatory cytokines and recruit cytotoxic T
lymphocytes, NK cells, and neutrophils that contribute to
B cell depletion and amplify local inflammatory responses.
A role for Fc RI/III  CD11b  (phagocytic) cells has been
demonstrated for mAb-induced solid tumor regression,
with the conclusion that activated macrophages induce the
expansion of tumor-eliminating cytotoxic T cells (43).
However, T cells and NK cells did not play a measurable
role in B cell depletion after anti-CD20 mAb treatment
(Fig. 5). CD20-directed therapy is largely thought to also
involve C activation (16), and the anti-CD20 mAbs used in
this study activate C in vitro (Fig. 4 A). However, there
was no evidence that classical or alternative pathway C ac-
Figure 3. B cell depletion is Fc R dependent. (A) Blood B
cell depletion after MB20-11 ( ) or isotype control ( )
mAb treatment of FcR  / , Fc RI / , Fc RII / , and
Fc RIII /  mice on day 0. Values indicate mean circulat-
ing B cell numbers (  SEM, per ml) before (time 0) and 1 h
or 2, 4, or 7 d after mAb treatment (five or more mice per
time point). (B) Representative spleen B cell depletion 7 d
after mAb treatment. Numbers indicate the percentage of
B220  lymphocytes within the indicated gates. (C) Mean
spleen B cell numbers (  SEM) 7 d after MB20-11 (solid
bars) or isotype control (open bars) mAb treatment (five or
more mice per group). Numbers indicate the mean relative
percentage of B220  lymphocytes in anti-CD20 mAb–
treated mice compared with control mAb–treated litter-
mates. (D) B cell depletion after MB20-1 ( ) or isotype
control ( ) mAb treatment of FcR  /  littermates on day
0 compared with MB20-1 ( ) or isotype control ( ) mAb
treatment of WT littermates on day 0. Representative
spleen B cell depletion 7 d after MB20-1 or control mAb
treatment of FcR  /  littermates. Numbers indicate the
percentage of B220  lymphocytes. Bar graphs represent
mean spleen B cell numbers (  SEM) 7 d after MB20-1 or
isotype control mAb treatment of FcR  /  (solid bars)
or WT (open bars) mice (five or more mice per group).
(E) Blood and spleen (day 7) B cell depletion after MB20-
18 ( ) or isotype control ( ) mAb treatment of FcR  / 
littermates on day 0 compared with MB20-18 ( ) or iso-
type control ( ) mAb treatment of WT littermates on
day 0. Histograms represent mean spleen B cell numbers
(  SEM) 7 d after MB20-18 or isotype control mAb treat-
ment of FcR  /  (solid bars) or WT (open bars) mice (five
or more mice per group). (A–E) Significant differences
between mean results for MB20 or isotype control mAb–
treated mice are indicated. *, P   0.05; **, P   0.01.Monocytes Mediate B Cell Depletion during Anti-CD20 Immunotherapy 1664
tivation contributed significantly to B cell depletion in vivo
in this mouse model system (Fig. 4, B–D). Consistent with
the current findings using genetically modified mice, previ-
ous in vivo studies found that C depletion had no effect on
mAb-induced suppression of human melanoma and carci-
noma in nude mice, whereas macrophage inactivation by
silica treatment abolished tumor suppression (44). Studies
using anti-CD8 mAbs have also documented the impor-
tance of Fc R in the clearance of CD8  cells and have
shown that C activation is not necessary for the killing of
CD8  cells in vivo (45, 46). Also consistent with anti-
CD20 therapy primarily involving Ab-dependent cellular
cytotoxicity, higher response rates are observed in lym-
phoma clinical trials when Rituximab therapy is combined
with agents that enhance cellular cytotoxicity (47). Thus,
tissue macrophages appear critical for B cell depletion after
anti-CD20 mAb treatment.
Optimal anti-CD20 mAb-induced B cell depletion cor-
related closely with mAb isotype, with IgG2a   IgG1  
IgG2b    IgG3 (Fig. 2 B and Table I). These isotype-
specific effects of anti-CD20 mAbs correlate closely with
Fc RI and Fc RIII specificities (38). In addition, anti-
CD20 mAb therapy had modest, if any, effects in FcR  / 
mice, but was effective in both Fc RI /  and Fc RIII / 
mice (Fig. 3). The importance of mAb isotype in im-
munotherapy has long been appreciated, particularly for
mouse IgG2a Abs (44, 46, 48–50). This suggests that
monocyte expression of either high affinity Fc RI or low
affinity Fc RIII is sufficient for B cell depletion. Fc RI
function may actually dominate over Fc RIII function
when IgG2a anti–mouse CD20 mAbs were used because
blood and spleen B cell depletion were delayed or incom-
plete after MB20-11 mAb treatment in Fc RI /  mice,
but not in Fc RIII /  mice (Fig. 3 A). The in vivo de-
pendence of IgG2a mAb potency on Fc RI function has
also been observed in other experimental systems (39, 51,
52). However, this result was unexpected because Fc RI
normally appears to play a minor role in vivo because ad-
ministered mAbs must compete with intrinsic circulating
antibodies for high affinity Fc RI interactions (39, 52).
Moreover, Fc RIII /  and FcR  /  mice normally ex-
hibit remarkably similar phenotypes during IgG-dependent
immune responses (37). Thus, limited MB20-11 mAb
binding to Fc RI may mediate efficient B cell phagocyto-
sis due to high mAb potency, a high affinity for CD20,
or its use at relatively high concentrations. Otherwise,
MB20-11 mAb may effectively use the low affinity
FcgRIII to mediate B cell depletion in the absence of
Fc RI function as occurs with an IgG2a mAb reactive
with RBCs in a mouse model of hemolytic anemia (53).
Although Fc RI is reported to bind mouse IgG3 (54),
IgG3 anti–mouse CD20 mAbs had little effect in vivo
(Fig. 2 B). Extensive experiments to address the differen-
tial use of Fc RI or Fc RIII by anti-CD20 mAbs of dif-
ferent isotypes given at different doses are underway. In
mice, Fc RII engagement inhibits effector cell activation,
with genetic deletion of inhibitory Fc Rs triggering in-
creased susceptibility to immune complex–induced in-
flammation (55). Likewise, studies in CSF-1–deficient
op/op mice have shown that i.v.   globulin–mediated pro-
tection from pathogenic Ab-induced inflammation or throm-
bocytopenia is mediated through macrophage Fc RII (31,
56). Genetic deletion of inhibitory Fc Rs also enhances in
Figure 4. B cell depletion in vivo is C independent. (A) In vitro
C-dependent cytotoxicity of MB20 mAbs for spleen B cells. Values rep-
resent the mean (  SEM) percentage of B220  cells that were PI  in three
or more experiments. (B) B cell depletion after MB20-11 ( ) or isotype
control ( ) mAb treatment of C3 / , C4 / , or C1q /  mice on day 0.
Blood values indicate mean circulating B cell numbers (  SEM, per ml)
before (time 0) and 1 h or 2, 4, or 7 d after mAb treatment (five or more
mice per time point). Representative spleen B cell frequencies and mean B
cell numbers (  SEM) 7 d after MB20-11 (solid bars) and isotype control
(open bars) mAb treatment (five or more mice per group). (C and D) Blood
and spleen B cell depletion after MB20-1 or MB20-18 ( ) or isotype
control ( ) mAb treatment of C3 /  mice on day 0 compared with
MB20-1 or MB20-18 ( ) or isotype control ( ) mAb treatment of WT
mice on day 0. Representative spleen B cell depletion 7 d after MB20-1
or control mAb treatment of C3 /  littermates. Numbers indicate the
percentage of B220  lymphocytes within the indicated gates. Bar graphs
represent mean spleen B cell numbers (  SEM) 7 d after MB20-1 or iso-
type control mAb treatment of C3 /  (solid bars) or WT (open bars) mice
(five or more mice per group). (A–D) Significant differences between
mean results for MB20 or isotype control mAb–treated mice are indi-
cated. *, P   0.05; **, P   0.01.Uchida et al. 1665
vivo cytotoxicity against mAb-targeted tumors, including
Rituximab targeting of human lymphoma cells in nude
mice (26). Experiments to determine the extent that
FcgRII expression influences B cell depletion by mouse
anti–mouse CD20 mAbs of different isotypes given at dif-
ferent doses are underway because the current mechanistic
immunotherapy studies using native mouse mAbs may dif-
fer from previous studies using chimerized or humanized
mAbs bearing human Fc regions. Regardless, these results
clearly demonstrate that strategies to augment monocyte
Fc R expression and function in vivo should result in
more effective immunotherapies (26). Moreover, the cur-
rent observations corroborate studies in lupus and lymphoma
patients showing that human Fc RIIa and Fc RIIIa poly-
morphisms correlate with the efficiency of tumor and B
cell depletion during anti-CD20 mAb therapy (57–59).
Consistent with an essential role for macrophages in B cell
depletion after anti-CD20 mAb treatment, responses to
Rituximab therapy also correlate with polymorphisms in
human Fc RIIa, which is only expressed on macrophages
and DCs (59). Collectively, these results indicate that the
most important factor influencing anti-CD20 mAb effi-
cacy in vivo is the mAb isotype and its capacity to interact
with monocyte Fc R.
Although almost all of the anti–mouse CD20 mAbs in
this study induced C-dependent killing in vitro (Fig. 4 A),
there was no direct correlation between C activation in
vitro and B cell depletion in vivo (Figs. 2 B and 4 A). Like-
wise, isotype-specific B cell depletion by the anti-CD20
mAbs contrasted with the relative abilities of the different
anti-CD20 mAbs to initiate C-dependent cytotoxicity in
vitro (Fig. 4 A) and the known isotype-specific abilities of
mouse Abs to effectively activate mouse C, IgG2a   IgG2b  
IgG3, but not IgG1 (60, 61). In vivo B cell depletion
with anti-CD20 mAbs (Fig. 2 B) also contrasted with the
isotype-specific abilities of mouse Abs to initiate C-depen-
dent cytotoxicity (IgG2a   IgG2b   IgG3   IgG1) of
lymphoma cells in vivo (49). Although IgG2b and IgG3
mAbs are highly pathogenic, their effectiveness is due in
part to their ability to induce C activation in addition to
the ability of IgG2b mAbs to bind Fc RI and Fc RIII
(51). IgG1 mAbs had low pathogenicity in this mouse
model of Ab-induced anemia, but they were not effective
in C activation. By contrast, IgG2b and IgG1 anti–mouse
CD20 mAbs depleted blood and tissue B cells to the same
extent in WT and C3 /  mice (Fig. 4, C and D), whereas
IgG3 anti-CD20 mAbs had little effect on B cell numbers
(Fig. 2 B). Thus, C activation does not appear to influence
the efficacy of anti-CD20 mAbs in vivo. Similarly, Fc R-
mediated erythrophagocytosis is the major pathogenic mech-
anism responsible for autoimmune hemolytic anemia in
mice, with C-mediated hemolysis and erythrophagocy-
tosis playing a minor, if any, role (39, 62, 63). Recently,
the protective activities of Rituximab (human IgG1 chi-
Figure 5. Monocytes mediate B cell depletion. WT
mice were treated with clodronate (CLOD) as shown
(arrows) to deplete macrophages, whereas other mice had
genetic deficiencies in leukocyte subpopulations. (A) Blood B
cell depletion after MB20-11 ( ) or isotype control ( )
mAb treatment on day 0. For clodronate-treated mice,
blood B cell numbers were determined 1 h and 2, 4, and
7 d after mAb treatment, with the vertical dashed line indi-
cating time 0 mAb treatment. For CSF1op mice, circulating
B cell numbers were not quantified 1 h after mAb treat-
ment because of the small size of these mice and the risk
for mortality. B cell numbers at 1-h time points are shown
for the other mouse genotypes. (B) Representative flow
cytometry analysis and mean spleen B cell numbers (  SEM)
7 d after MB20-11 (solid bars) or isotype control (open
bars) mAb treatment (five or more mice per group). Signif-
icant differences between mean results from isotype con-
trol or MB20 mAb–treated cells are indicated. *, P   0.05;
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mera) and the 1F5 (mouse IgG2a) anti–human CD20
mAbs in a mouse tumor model have been reported to be
completely absent in C1q /  mice (16). However, tissue B
cell depletion by the MB20-11 IgG2a anti–mouse CD20
mAb was not affected by C1q deficiency (Fig. 4 B). Al-
though simple explanations for these different results are
not obvious, the fine specificities of different anti–human
CD20 mAbs was recently reported to influence their in
vivo effects (64). Although C activation by Rituximab and
the 1F5 mAb is critical for lymphoma therapy in xe-
notransplantation models, the B1 (IgG2a) mAb was also ef-
fective but did not depend on C activation in vivo (64), al-
though it effectively activates C in vitro (65). Furthermore,
F(ab )2 fragments of the B1 mAb, but not the 1F5 mAb,
were therapeutically effective, indicating that non-Fc–
dependent mechanisms are involved with the B1 mAb,
which was able to induce higher levels of apoptosis than
Rituximab and 1F5. Why these IgG2a anti–human CD20
mAbs have similar in vivo effects but are thought to use en-
tirely different effector mechanisms is unclear. Moreover,
both proposed mechanisms contrast with the mechanism of
action of the IgG2a anti–mouse CD20 mAbs examined in
this study. Perhaps these studies collectively demonstrate
that in vitro measurements may not completely reflect
what is relevant in vivo and that mAb activity in vitro may
not predict in vivo function (45).
Although Fc R-mediated cytotoxicity appears to be the
major effector mechanism for B cell depletion, factors in
addition to mAb isotype and C activation are nonetheless
important for mAb therapeutic efficacy. Additional impor-
tant factors include the following: mAb affinity and avidity,
mAb half-life in vivo, mAb effects on B cell function, the
density and distribution of mAb binding sites on the target
molecule, mAb effects on target molecule function (agonis-
tic, antagonistic), and the efficiency of target molecule
cross-linking by the mAb. Others have shown that CD20
density determines the in vitro susceptibility of malignant B
cells to Rituximab and C (14). Because the density of indi-
vidual mAbs binding to B cells (Table I and Fig. 1 C) did
not correlate with their effectiveness for B cell depletion
(Table I), this implies that mAb density on the cell surface
is not the primary factor inducing optimal Ab-dependent
cellular cytotoxicity–mediated clearance. Rather, the cur-
rent studies demonstrate that mAb isotype is a more critical
factor. Likewise, isotype-specific differences in mAb half-
life did not correlate with anti-CD20 mAb-induced B cell
depletion because mAb effectiveness was readily apparent
within 48 h of treatment (Fig. 2 C) and IgG2b is cleared
faster than IgG1   IgG3   IgG2a from serum (49). How-
ever, a longer mAb half-life in vivo is predicted to provide
more durable B cell depletion in this model system. The ef-
ficiency of target molecule cross-linking by therapeutic
mAbs and Fc R-expressing effector cells may also contrib-
ute to therapeutic outcome (66) because anti-CD20 mAb-
induced signaling is often enhanced by hyper cross-linking
(13, 67, 68). Thus, individual characteristics and the thera-
peutic advantages of each individual mAb would become
more obvious if all 12 of the mAbs tested in this study had
been of the same isotype. Nevertheless, heterogeneity be-
tween individual mAbs was demonstrated in this study with
IgG2b anti-CD20 mAbs. For example, the MB20-18 mAb
was effective at depleting both circulating and spleen B
cells, whereas the MB20-7 mAb cleared most, but not all,
circulating B cells and had only modest effects on spleen B
cells. By contrast, the MB20-8 and MB20-10 mAbs did
not induce rapid clearance of circulating B cells and did not
affect spleen B cell numbers. The superior B cell depletion
activity of the MB20-18 mAb relative to the other three
IgG2b mAbs (Fig. 2 B) may relate to the fact that it bound
to the surface of B cells at the highest levels of all anti–
mouse CD20 mAbs (Table I and Fig. 1 C). Although the
IgG2a and IgG1 anti-CD20 mAbs generally generated ho-
mogenous levels of B cell clearance, this is likely to reflect
the fact that maximal B cell depletion was observed under
the conditions tested. Thus, multiple factors affect the in
vivo effectiveness of anti-CD20 mAb-induced B cell clear-
ance, although mAb isotype was the most critical factor.
Human studies of anti-CD20 therapy are primarily fo-
cused on blood B cells or lymphoblastoid cell lines, rather
than tissue B cells. However, the immunotherapy model
used in this study indicates that although blood B cell de-
pletion is rapid, it may not be an accurate indicator for
anti-CD20 mAb effects on tissue B cells. For example,
most anti-CD20 mAbs induced rapid depletion of circulat-
ing B cells within 1–48 h, whereas IgG2b and IgG3 anti-
CD20 mAbs had modest, if any, effects on spleen B cells
(Figs. 2, B and D, 3, and 4). Most circulating B cells did
not reappear during these time periods, which strongly
suggesting that they may have been killed and not merely
sequestered. Because i.v. administration of clodronate lipo-
somes preferentially depletes splenic and liver macrophages
(35), and circulating B cells were not rapidly cleared in clo-
dronate-treated mice (Fig. 5 A), the spleen and liver might
be among the most likely sites for circulating and tissue B
cell depletion. Rapid B cell depletion from blood is also
observed in patients after anti-CD20 mAb infusion (10–12,
69). These results suggest that different B cell subpopula-
tions may have different sensitivities to anti-CD20 therapy
or that B cells present in different anatomical locations
might be differentially affected. Alternatively, B cell deple-
tion from the circulation may involve pathways in addition
to Fc R-mediated phagocytosis or may reflect B cell mi-
gration into tissues rather than reflect B cell destruction.
This possibility is supported by observations that some
anti–human CD20 mAbs have potent physiologic effects
on blood B cells and influence in vitro homotypic adhe-
sion, Ca2  influx, cell cycle regulation, and survival/apop-
tosis (1). Consistent with this, Fc RIIIa polymorphisms are
not predictive of patient responses in chronic lymphocytic
leukemia, which most commonly involves blood and mar-
row (70), whereas they are predictive of tumor clearance in
follicular lymphomas (57, 59) where Ab-dependent cellular
cytotoxicity appears critical (Figs. 3 and 4). Regardless, the
current animal model allows these issues to be assessed di-Uchida et al. 1667
rectly and may provide additional understanding of the
molecular mechanisms and pathways invoked during anti-
CD20 therapy in vivo.
The use of 12 different anti-CD20 mAbs in this study
has provided a unique opportunity to define the ability
of individual mouse IgG isotopes in relation to B cell
clearance and Fc R-dependent effector functions in the
clearance of B cells during immunotherapy. Macrophage-
mediated B cell depletion during anti-CD20 therapy has
far-reaching clinical implications, which may also be appli-
cable to other cell-directed mAb therapies. For example,
augmenting monocyte numbers or function may increase
anti-CD20 mAb effectiveness in vivo. In support of this
concept, clinical studies showing that GM-CSF treatment
or priming of neutrophils may improve the effectiveness of
mAb-based therapies (71–74), although neutrophils were
not implicated in anti-CD20 mAb depletion of B cells in
this study. Similarly, immunotherapy effectiveness might
be reduced in diseases with concomitant myelosuppression
or immunosuppression, similar to the effects of clodronate
on B cell depletion in this study (Fig. 5). Although early B
cell depletion is observed in most patients with refractory
non-Hodgkin’s lymphoma after anti-CD20 therapy, only
40–60% of patients show a durable clinical response (75,
76). The unexplained high rate of failure for anti-CD20
therapy may in some cases result from concomitant myelo-
suppression or reduced numbers of tissue monocytes. This
may also explain, in part, why disease progression can con-
tinue during mAb therapy despite continued CD20 expres-
sion by malignant cells (12). Variable depletion of effector
monocytes may also explain why anti-CD20 mAb therapy
is more effective as an initial therapy, in contrast to results
obtained after patients relapse after chemotherapy (9). Be-
cause monocytes were found to provide a fundamental and
essential mechanism for B cell depletion, there is critical
need for a better understanding of monocyte function in
patients with lymphoma and autoimmune disease undergo-
ing mAb-based therapies.
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